{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:45:20Z","timestamp":1789595120751,"version":"build-2803163510"},"reference-count":40,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Elmeco Hormonal Implants"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Gestrinone (R-2323), or ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group more commonly used as an oral, intravaginal, or subcutaneous implant for the treatment of endometriosis, contraception, and estrogen-dependent conditions such as hypermenorrhea, premenstrual dysphoria, and intense menstrual cramps. This review aims to reevaluate the routes, doses, and applicability proposed for using gestrinone, including its use in new conditions such as menopause, lipedema, and sarcopenia. Here, we present the possible application of gestrinone as a long-acting therapeutic possibility through hormonal implants and the benefits and potential risks. Available evidence on the safety of doses and routes is limited. Gestrinone appears to be effective compared to other progestins and may have some advantages in the treatment of estrogen-dependent pathologies. Future research must evaluate gestrinone\u2019s long-term safety and potential therapeutic indications.<\/jats:p>","DOI":"10.3390\/ph17091248","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T03:36:38Z","timestamp":1727062598000},"page":"1248","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7940-3667","authenticated-orcid":false,"given":"Guilherme","family":"Renke","sequence":"first","affiliation":[{"name":"Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Antunes","sequence":"additional","affiliation":[{"name":"Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Sakata","sequence":"additional","affiliation":[{"name":"Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Tostes","sequence":"additional","affiliation":[{"name":"Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0010-7824(75)90059-1","article-title":"Contraceptive effectiveness of Silastic implants containing the progestin R-2323","volume":"11","author":"Coutinho","year":"1975","journal-title":"Contraception"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","article-title":"Classification and pharmacology of progestins","volume":"61","author":"Schindler","year":"2008","journal-title":"Maturitas"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5114\/pm.2016.58773","article-title":"Aromatase inhibitors in the treatment of endometriosis","volume":"1","year":"2016","journal-title":"Menopausal Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0020-7292(84)90067-5","article-title":"Treatment of fibrocystic disease of the breast with gestrinone, a new trienic synthetic steroid with anti-estrogen, anti-progesterone properties","volume":"22","author":"Coutinho","year":"1984","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.trsl.2021.12.002","article-title":"Repurposing gestrinone for tumor suppressor through P21 reduction regulated by JNK in gynecological cancer","volume":"243","author":"Ciou","year":"2022","journal-title":"Transl. Res."},{"key":"ref_6","unstructured":"Tostes, F. (2020). Effects of Exposing Different Cell Lines to Gestrinone. [Master\u2019s Thesis, Multicenter Postgraduate Program in Biochemistry and Molecular Biology\u2014Federal University of Rio de Janeiro]."},{"key":"ref_7","unstructured":"American Cancer Society (2024, February 20). About Breast Cancer 2022. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/breast-cancer-facts-figures.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4274\/ejbh.galenos.2021.6213","article-title":"Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study","volume":"17","author":"Donovitz","year":"2021","journal-title":"Eur. J. Breast Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/GME.0000000000000096","article-title":"Rapid response to breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: Neoadjuvant hormone therapy in breast cancer","volume":"21","author":"Glaser","year":"2014","journal-title":"Menopause"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.maturitas.2015.06.002","article-title":"Testosterone and breast cancer prevention","volume":"82","author":"Glaser","year":"2015","journal-title":"Maturitas"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0303-7207(02)00105-3","article-title":"Breast Cancer: From Estrogen To Androgen Receptor","volume":"193","author":"Ando","year":"2002","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJM199506153322401","article-title":"The use of estrogens and progestins and the risk of breast cancer in postmenopausal women","volume":"332","author":"Colditz","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00002512-200421130-00004","article-title":"New progestogens: A review of their effects in perimenopausal and postmenopausal women","volume":"21","year":"2004","journal-title":"Drugs Aging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.biopha.2012.02.003","article-title":"Gestrinone inhibits growth of human uterine leiomyoma may relate to activity regulation of ER\u03b1, Src and P38 MAPK","volume":"66","author":"Zhu","year":"2012","journal-title":"Biomed. Pharmacother"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gestrinone Italian Study Group (1996). Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertil Steril, 66, 911\u2013919.","DOI":"10.1016\/S0015-0282(16)58682-8"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000291809","article-title":"Comparative Effect of the Calcium Antagonist Verapamil and the Synthetic Steroids Gestrinone and Danazol on Human Monocyte Phagocytosis in vitro","volume":"43","author":"Magri","year":"1997","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_17","unstructured":"(2024, September 14). Eshre, Guideline Endometriosis. Available online: https:\/\/www.Eshre.Eu\/Guideline\/Endometriosis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0015-0282(16)60722-7","article-title":"Long-Term Treatment of Leiomyomas with Gestrinone","volume":"51","author":"Coutinho","year":"1989","journal-title":"Fertil Steril"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0010-7824(78)90090-2","article-title":"Comparative clinical trial of the progestins R-2323 and levonorgestrel administered by subdermal implants","volume":"18","author":"Alvarez","year":"1978","journal-title":"Contraception"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Renke, G., and Callizo, C. (2023). Clinical Approaches to Nestorone Subdermal Implant Therapy in Women\u2032s Health. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092586"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neubiorev.2020.12.007","article-title":"Progress in progestin-based therapies for neurological disorders","volume":"122","author":"Bonsack","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.brainres.2018.10.014","article-title":"Beyond contraception and hormone replacement therapy: Advancing Nestorone to a neuroprotective drug in the clinic","volume":"1704","author":"Tuazon","year":"2019","journal-title":"Brain Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0002-9378(97)70504-0","article-title":"Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis","volume":"176","author":"Dawood","year":"1997","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Poojari, A., and Dev, K. (2022). Lipedema: Insights into Morphology, Pathophysiology, and Challenges. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123081"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Renke, G., and Tostes, F. (2023). Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We?. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040619"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/GME.0000000000002335","article-title":"Use of menopausal hormone therapy beyond age 65 years and its effects on women\u2032s health outcomes by types, routes, and doses","volume":"31","author":"Baik","year":"2024","journal-title":"Menopause"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e060223213459","DOI":"10.2174\/1573403X19666230206130205","article-title":"Cardio-Metabolic Health and HRT in Menopause: Novel Insights in Mitochondrial Biogenesis and RAAS","volume":"19","author":"Renke","year":"2023","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dinu, M.D., and Haj Hamoud, B. (2024). Endometriosis in Menopausal Women-A New Age Is Coming? Literature Review. Life, 14.","DOI":"10.3390\/life14040485"},{"key":"ref_29","first-page":"1091","article-title":"Oral gestrinone: A novel antiprogestin with no antitumor activity in endocrine-sensitive breast cancer","volume":"71","author":"Cunningham","year":"1987","journal-title":"Cancer Treat Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0015-0282(16)53273-7","article-title":"A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis","volume":"53","author":"Hornstein","year":"1990","journal-title":"Fertil Steril"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0015-0282(16)60969-X","article-title":"Endocrine, metabolic, and clinical effects of gestrinone in women with endometriosis","volume":"52","author":"Venturini","year":"1989","journal-title":"Fertil Steril"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0015-0282(16)59765-9","article-title":"Treatment of endometriosis by vaginal administration of gestrinone","volume":"49","author":"Coutinho","year":"1988","journal-title":"Fertil Steril"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/aogs.1989.68.s150.39","article-title":"Gestrinone in the treatment of myomas","volume":"150","author":"Coutinho","year":"1989","journal-title":"Acta Obs. Gynecol. Scand. Suppl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0002-9378(86)80016-3","article-title":"Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone","volume":"155","author":"Coutinho","year":"1986","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"350","DOI":"10.12891\/ceog2086.2016","article-title":"Effect of mifepristone in the different treatments of endometriosis","volume":"43","author":"Zhang","year":"2016","journal-title":"Clin. Exp. Obs. Gynecol."},{"key":"ref_36","first-page":"577","article-title":"Effects of gestrinone on serum lipid and lipoprotein levels in women with endometriosis","volume":"41","author":"Fukuda","year":"1989","journal-title":"Nihon Sanka Fujinka Gakkai Zasshi"},{"key":"ref_37","first-page":"21","article-title":"Evaluation of Safety and Effectiveness of Gestrinone in the Treatment of Endometriosis: A Systematic Review and Meta-Analysis","volume":"307","author":"Ferrari","year":"2023","journal-title":"Arch Gynecol. Obs."},{"key":"ref_38","unstructured":"(2024, September 14). Clinicaltrials.gov (Identifier NCT05570786), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05570786?cond=gestrinone&rank=2."},{"key":"ref_39","unstructured":"(2024, September 14). Clinicaltrials.gov (Identifier NCT06543550), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06543550?cond=gestrinone&rank=3."},{"key":"ref_40","unstructured":"(2024, September 14). Clinicaltrials.gov (Identifier NCT06402344), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06402344?cond=gestrinone&rank=1."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/9\/1248\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:02:20Z","timestamp":1760112140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/9\/1248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ph17091248"],"URL":"https:\/\/doi.org\/10.3390\/ph17091248","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,22]]}}}